iCeutica sold to US partner Iroko

摘要

iCeutica is a venture that resulted from a project conducted at the University of Western Australia during 2003. With an objective to reduce particle size, researchers used dry milling technology originating from mineral processing operations and applied it to more delicate pharmaceutical compounds. The objective was to reduce the particle size of pharmaceuticals to nano scale, and thereby make them suitable for reformulation into new pharmaceutical products with improved properties. The work resulted in the proprietary SoluMatrix dry milling methodology, which both grinds the drug particles into a superfine powder and protects those nanoparticles from subsequent agglomeration. SoluMatrix powders are easy to formulate into tablets, capsules and a range of other dosage forms for oral delivery routes as well as inhalable, intranasal and injectable delivery routes.